Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Coronary Heart Disease Due to Combined Estrogen Plus Progestin Therapy

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 36, Issue 2, 2016, Pages 418-424

  Johnson, Karen C ^a   Aragaki, Aaron K ^b   Jackson, Rebecca ^b,c,e   Reiner, Alex ^a   Sandset, Per Morten ^d   Rosing, Jan ^a   Dahm, Anders E A ^d   Rosendaal, Frits ^f   Manson, Joann E ^g   Martin, Lisa W ^h   Liu, Simin ⁱ   Kuller, Lewis H ^j   Cushman, Mary ^k   Rossouw, Jacques E ^l  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b USA   (United States)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e MAASTRICHT UNIVERSITY   (Netherlands)

^f LEIDEN UNIVERSITY   (Netherlands)

^g HARVARD UNIVERSITY   (United States)

^h GEORGE WASHINGTON UNIVERSITY   (United States)

ⁱ BROWN UNIVERSITY   (United States)

^j UNIVERSITY OF PITTSBURGH   (United States)

^k UNIVERSITY OF VERMONT   (United States)

^l NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

more..

Author keywords

activated protein C resistance; coronary disease; estrogens; hemostatics; progestins; tissue factor pathway inhibitor activity

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN; GESTAGEN; TISSUE FACTOR PATHWAY INHIBITOR; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR;

ACTIVATED PROTEIN C RESISTANCE; AGED; ANALYSIS; ARTICLE; BLOOD CLOTTING PARAMETERS; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENOTYPE; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; NORMALIZED ACTIVATED PROTEIN C RESISTANCE RATIO; PRIORITY JOURNAL; ADVERSE EFFECTS; BLOOD; CHEMICALLY INDUCED; COMPLICATION; CORONARY DISEASE; ESTROGEN THERAPY; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSTMENOPAUSE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR;

ACTIVATED PROTEIN C RESISTANCE; AGED; BIOMARKERS; CASE-CONTROL STUDIES; CORONARY DISEASE; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; LIPOPROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSTMENOPAUSE; PROGESTINS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 84955725930     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.115.306905     Document Type: Article

References (31)

1. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002 288 321 333
2. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M, Women's Health Initiative Investigators Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003 349 523 534. doi: 10.1056/NEJMoa030808.
3. Smith A, Patterson C, Yarnell J, Rumley A, Ben-Shlomo Y, Lowe G, Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation 2005 112 3080 3087. doi: 10.1161/CIRCULATIONAHA.105.557132.
4. Sandset PM, Hoibraaten E, Eilertsen AL, Dahm A, Mechanisms of thrombosis related to hormone therapy. Thrombosis Research 2009 123 suppl E S70 S73
5. Høibraaten E, Qvigstad E, Andersen TO, Mowinckel MC, Sandset PM, The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism-results from a randomized, double-blind, clinical trial. Thromb Haemost 2001 85 775 781
6. Hoibraaten E, Mowinckel M-C, De Ronde H, Bertina RM, Sandset PM, Hormone replacement therapy and acquired resistance to protein C: results of a randomized, double-blind, placebo-controlled trial. British J Haematol 2001 115 415 420
7. Curvers J, Thomassen MC, Nicolaes GA, Van Oerle R, Hamulyak K, Hemker HC, Tans G, Rosing J, Acquired APC resistance and oral contraceptives: differences between two functional tests. Br J Haematol 1999 105 88 94
8. Eilertsen AL, Liestøl S, Mowinckel MC, Hemker HC, Sandset PM, Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system. Thromb Haemost 2007 97 938 943
9. Eilertsen AL, Sandvik L, Mowinckel MC, Andersen TO, Qvigstad E, Sandset PM, Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis. Thromb Res 2007 120 371 379. doi: 10.1016/j.thromres.2006.10.013.
10. Raps M, Helmerhorst FM, Fleischer K, Dahm AE, Rosendaal FR, Rosing J, Reitsma P, Sandset PM, van Vliet HA, The effect of different hormonal contraceptives on plasma levels of free protein S and free TFPI. Thromb Haemost 2013 109 606 613. doi: 10.1160/TH12-10-0771.
11. van Vliet HA, Bertina RM, Dahm AE, Rosendaal FR, Rosing J, Sandset PM, Helmerhorst FM, Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor. J Thromb Haemost 2008 6 346 351. doi: 10.1111/j.1538-7836.2007.02863.x.
12. Bladbjerg EM, Madsen JS, Kristensen SR, Abrahamsen B, Brixen K, Mosekilde L, Jespersen J, Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. J Thromb Haemost 2003 1 1208 1214
13. Rossouw JE, Cushman M, Greenland P, Lloyd-Jones DM, Bray P, Kooperberg C, Pettinger M, Robinson J, Hendrix S, Hsia J, Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the women's health initiative trials of hormone therapy. Arch Intern Med 2008 168 2245 2253. doi: 10.1001/archinte.168.20.2245.
14. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, Sidney S, Rosendaal FR, Women's Health Initiative Investigators Estrogen plus progestin and risk of venous thrombosis. JAMA 2004 292 1573 1580. doi: 10.1001/jama.292.13.1573.
15. van Langevelde K, Flinterman LE, van Hylckama Vlieg A, Rosendaal FR, Cannegieter SC, Broadening the factor V Leiden paradox: pulmonary embolism and deep-vein thrombosis as 2 sides of the spectrum. Blood 2012 120 933 946. doi: 10.1182/blood-2012-02-407551.
16. Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, Collins R, Danesh J, Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006 367 651 658. doi: 10.1016/S0140-6736(06)68263-9.
17. Kim RJ, Becker RC, Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J 2003 146 948 957. doi: 10.1016/S0002-8703(03)00519-2.
18. Tans G, van Hylckama Vlieg A, Thomassen MC, Curvers J, Bertina RM, Rosing J, Rosendaal FR, Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol 2003 122 465 470
19. Winckers K, Siegerink B, Duckers C, Maurissen LF, Tans G, Castoldi E, Spronk HM, Ten Cate H, Algra A, Hackeng TM, Rosendaal FR, Increased tissue factor pathway inhibitor activity is associated with myocardial infarction in young women: results from the RATIO study. J Thromb Haemost 2011 9 2243 2250. doi: 10.1111/j.1538-7836.2011.04497.x.
20. Kiechl S, Muigg A, Santer P, Mitterer M, Egger G, Oberhollenzer M, Oberhollenzer F, Mayr A, Gasperi A, Poewe W, Willeit J, Poor response to activated protein C as a prominent risk predictor of advanced atherosclerosis and arterial disease. Circulation 1999 99 614 619
21. Winckers K, ten Cate H, Hackeng TM, The role of tissue factor pathway inhibitor in atherosclerosis and arterial thrombosis. Blood Rev 2013 27 119 132. doi: 10.1016/j.blre.2013.03.001.
22. Dahm A, Van Hylckama Vlieg A, Bendz B, Rosendaal F, Bertina RM, Sandset PM, Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 2003 101 4387 4392. doi: 10.1182/blood-2002-10-3188.
23. Zakai NA, Lutsey PL, Folsom AR, Heckbert SR, Cushman M, Total tissue factor pathway inhibitor and venous thrombosis. The Longitudinal Investigation of Thromboembolism Etiology. Thromb Haemost 2010 104 207 212. doi: 10.1160/TH09-10-0693.
24. Morange PE, Simon C, Alessi MC, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Juhan-Vague I, PRIME Study Group Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation 2004 109 1343 1348. doi: 10.1161/01.CIR.0000120705.55512.EC.
25. Mitchell CT, Kamineni A, Palmas W, Cushman M, Tissue factor pathway inhibitor, vascular risk factors and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2009 207 277 283. doi: 10.1016/j.atherosclerosis.2009.04.024.
26. Rossouw JE, Johnson KC, Pettinger M, Cushman M, Sandset PM, Kuller L, Rosendaal F, Rosing J, Wasserthal-Smoller S, Martin LW, Manson JE, Lakshminarayan K, Merino JG, Lynch J, Tissue factor pathway inhibitor, activated protein C resistance, and risk of ischemic stroke due to postmenopausal hormone therapy. Stroke 2012 43 952 957. doi: 10.1161/STROKEAHA.111.643072.
27. Dahm AE, Sandset PM, Rosendaal FR, The association between protein S levels and anticoagulant activity of tissue factor pathway inhibitor type 1. J Thromb Haemost 2008 6 393 395. doi: 10.1111/j.1538-7836.2007.02859.x.
28. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH, Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993 341 1165 1168
29. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE, Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994 343 940 943
30. Rossouw JE, Prentice RL, Manson JE, Aragaki AK, Hsia J, Martin LW, Kuller L, Johnson KC, Eaton C, Jackson R, Trevisan M, Allison M, Hoogeveen RC, Relationships of coronary heart disease with 27-hydroxycholesterol, low-density lipoprotein cholesterol, and menopausal hormone therapy. Circulation 2012 126 1577 1586. doi: 10.1161/CIRCULATIONAHA.112.103218.
31. Wild RA, Wu C, Curb JD, Martin LW, Phillips L, Stefanick M, Trevisan M, Manson JE, Coronary heart disease events in the Women's Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women's Health Initiative randomized clinical trials. Menopause 2013 20 254 260